Black transgender women and the HIV care continuum; PrEP uptake potential among trans women; an update on U.S. mother-to-child HIV transmission; is extra measles vaccination necessary?
The benefits of pre-pregnancy HIV treatment initiation for mothers-to-be; HIV diagnoses rise among young U.S. MSM; cost effectiveness of PrEP for heterosexual women; methotrexate and arterial function.
"It is hard to imagine how in 2018 we could be in this situation where women with HIV are being so woefully underserved," Polly Clayden writes.
A recent case study illustrates the complexity of managing women in early stages of pregnancy presenting on a dolutegravir-based regimen, and the need for careful consideration when responding to new data.
The manufacturer of darunavir/cobicistat (Prezcobix) has issued a Dear Doctor letter warning about use of the drug during pregnancy due to significantly reduced plasma levels of the drug during the second and third trimesters.
A drug combination aimed at preventing transmission of HIV from a pregnant woman to her fetus likely does not increase the risk for preterm birth and early infant death, according to a re-analysis of two studies.
This recently updated fact sheet from the U.S. Centers for Disease Control and Prevention provides a quick rundown of the latest HIV infection numbers and prevention challenges impacting new moms and moms-to-be.
In our final installment of 2017, we intermingle forward-looking research with some retrospective analysis. We begin our four-study tour by joining researchers in Tennessee for an exercise in HIV outbreak prediction.
The British HIV Association has taken the unusual step of issuing a statement to publicly challenge a recent paper from the British Medical Journal.
"We were, frankly, shocked and appalled to see a CDC guidance rife with outdated and misleading information that implied otherwise," JD Davids states. "Today, CDC has not only corrected these errors but also released an updated analysis that shows re...